Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) EBITDA (2022 - 2025)

Historic EBITDA for Envoy Medical (COCH) over the last 4 years, with Q3 2025 value amounting to -$6.5 million.

  • Envoy Medical's EBITDA fell 875.69% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.8 million, marking a year-over-year decrease of 336.86%. This contributed to the annual value of -$20.8 million for FY2024, which is 3049.29% up from last year.
  • Per Envoy Medical's latest filing, its EBITDA stood at -$6.5 million for Q3 2025, which was down 875.69% from -$5.7 million recorded in Q2 2025.
  • In the past 5 years, Envoy Medical's EBITDA registered a high of $1.6 million during Q3 2023, and its lowest value of -$13.3 million during Q1 2023.
  • In the last 4 years, Envoy Medical's EBITDA had a median value of -$5.0 million in 2025 and averaged -$5.5 million.
  • Data for Envoy Medical's EBITDA shows a peak YoY increase of 21639.34% (in 2023) and a maximum YoY decrease of 136967.46% (in 2023) over the last 5 years.
  • Envoy Medical's EBITDA (Quarter) stood at -$11.5 million in 2022, then surged by 57.35% to -$4.9 million in 2023, then rose by 5.66% to -$4.6 million in 2024, then tumbled by 40.32% to -$6.5 million in 2025.
  • Its EBITDA stands at -$6.5 million for Q3 2025, versus -$5.7 million for Q2 2025 and -$5.0 million for Q1 2025.